UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Journal of hepatology, 2019-05, Vol.70 (5), p.1019-1023

2019

Volltextzugriff (PDF)

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

Hepatology (Baltimore, Md.), 2014-01, Vol.59 (1), p.46-48

2014

Volltextzugriff (PDF)

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Liver international, 2017-08, Vol.37 (8), p.1253-1254

2017

Volltextzugriff (PDF)

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of hepatology, 2017-11, Vol.67 (5), p.918-924

2017

Volltextzugriff (PDF)

Prescription of new HCV-drugs - what has to be considered judicially

Zeitschrift fur Gastroenterologie, 2015-01, Vol.53 (1), p.43

Mauss, Stefan

2015

Volltextzugriff (PDF)

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Journal of hepatology, 2018-04, Vol.68 (4), p.663-671

2018

Volltextzugriff (PDF)

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Liver international, 2021-05, Vol.41 (5), p.949-955

2021

Volltextzugriff (PDF)

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Liver international, 2020-03, Vol.40 (3), p.539-548

2020

Volltextzugriff (PDF)

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Journal of viral hepatitis, 2021-10, Vol.28 (10), p.1474-1483

2021

Volltextzugriff (PDF)

Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

Hepatology (Baltimore, Md.), 2004-12, Vol.40 (6), p.1421-1425

2004

Volltextzugriff (PDF)

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2023-05, Vol.61 (5), p.489-503

2023

Volltextzugriff (PDF)

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2143-2154

2013

Volltextzugriff (PDF)

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Journal of hepatology, 2017-08, Vol.67 (2), p.420-422

2017

Volltextzugriff (PDF)

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Clinical gastroenterology and hepatology, 2023-03, Vol.21 (3), p.713-722.e3

2023

Volltextzugriff (PDF)

Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management

Journal of hepatology, 2006, Vol.44 (1 Suppl), p.S114-S118

Mauss, Stefan

2006

Volltextzugriff (PDF)

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Journal of hepatology, 2020-03, Vol.72 (3), p.431-440

2020

Volltextzugriff (PDF)

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Liver international, 2017-02, Vol.37 (2), p.205-211

2017

Volltextzugriff (PDF)

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Journal of viral hepatitis, 2021-11, Vol.28 (11), p.1660-1664

2021

Volltextzugriff (PDF)

A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance

Hepatology (Baltimore, Md.), 2004-07, Vol.40 (1), p.120-124

2004

Volltextzugriff (PDF)

Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection

Liver international, 2020-12, Vol.40 (12), p.2978-2981

2020

Volltextzugriff (PDF)

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Digestive diseases and sciences, 2016-10, Vol.61 (10), p.3061-3071

2016

Volltextzugriff (PDF)

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2155-2163

2013

Volltextzugriff (PDF)

Current recommendations for the treatment of chronic hepatitis C

Zeitschrift fur Gastroenterologie, 2014-10, Vol.52 (10), p.1185

2014

Volltextzugriff (PDF)

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Liver international, 2018-11, Vol.38 (11), p.1906-1910

2018

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

KollektionTaylor & Francis:Master (3349 titles)

Nur zeigenGeprüft (Peer-Review)

ThemaGastroenterology & Hepatology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(32)

Publikationsform

Artikel
(40)

Sprache

Englisch
(36)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(40)
Science & Technology
(40)
Humans
(27)
Hepatitis C
(19)
Male
(18)
Female
(17)
Middle Aged
(15)
Adult
(13)
Antiviral Agents - Therapeutic Use
(13)
Hepatitis
(12)
Hepatitis C, Chronic - Drug Therapy
(12)
Drug Therapy, Combination
(10)
Patients
(9)
Cirrhosis
(8)
Infectious Diseases
(8)
Treatment Outcome
(8)
Antiviral Agents
(7)
Germany
(7)
Hepacivirus - Genetics
(7)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Prescription of new HCV-drugs - what has to be considered judicially

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance

Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Current recommendations for the treatment of chronic hepatitis C

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Aktive Filter

Suchergebnisse filtern